uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Development of CE methods to analyze potential components of the angiogenic glycoprotein vascular endothelial growth factor 165
Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Physical and Analytical Chemistry, Analytical Chemistry.
Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Physical and Analytical Chemistry, Analytical Chemistry.
Show others and affiliations
2009 (English)In: Electrophoresis, ISSN 0173-0835, E-ISSN 1522-2683, Vol. 30, no 2, 315-324 p.Article in journal (Refereed) Published
Abstract [en]

The vascular endothelial growth factor 165 (VEGF165) is the predominant form of thecomplex VEGF family. This glycoprotein has, among others, an angiogenic effect inmany physiological and pathological events. For this reason, its roles as a biomarker andas a therapeutic drug have been considered. However, very little is known about theexistence of different forms of VEGF165 arising from glycosylation and other potentialPTMs. This aspect is crucial because it is known that for other glycoproteins the ratiobetween these isoforms actually acts as a biomarker for certain diseases and otherphysiological states. In addition, for therapeutic use of glycoproteins it is known that thebiological activity may differ for the various isoforms. In this work CE methods toseparate up to seven peaks without baseline resolution containing various forms ofVEGF165 are developed. Using a computer program previously developed in-house peakassignment could be performed with accuracy close to 100%. In this way, comparisonbetween recombinant human VEGF165 expressed in insect cells, which is a glycosylatingsystem, and in Escherichia coli cells, which are unable of performing glycosylation ofproteins, has been possible. The methods developed, besides providing informationabout the existence of several forms of VEGF165, mean a starting point that permits thestudy of the role of VEGF165 as a potential biomarker of different diseases and physiologicalprocesses and to perform quality control of the recombinant drug duringmanufacturing. To the best of our knowledge this is the first time that CE methods forVEGF165 have been developed.

Place, publisher, year, edition, pages
2009. Vol. 30, no 2, 315-324 p.
Keyword [en]
Angiogenesis, Biomarker, Glycoprotein, Isoform / VEGF
National Category
Chemical Sciences
Research subject
Analytical Chemistry
Identifiers
URN: urn:nbn:se:uu:diva-100697DOI: 10.1002/elps.200800140ISI: 000263708900003PubMedID: 19204948OAI: oai:DiVA.org:uu-100697DiVA: diva2:210814
Available from: 2009-04-06 Created: 2009-04-06 Last updated: 2011-03-30Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Bergquist, Jonas

Search in DiVA

By author/editor
Bergquist, Jonas
By organisation
Analytical Chemistry
In the same journal
Electrophoresis
Chemical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 811 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf